EP1949902B1 — USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
Assigned to Eisai R&D Management Co Ltd · Expires 2012-06-27 · 14y expired
What this patent protects
Disclosed are: a pharmaceutical composition having an excellent anti-tumor effect; and a therapeutic method for cancer. 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7 -methoxy-6-quinolinecarboxamide or an analogue thereof can be used in combination with a substance havin…
USPTO Abstract
Disclosed are: a pharmaceutical composition having an excellent anti-tumor effect; and a therapeutic method for cancer. 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7 -methoxy-6-quinolinecarboxamide or an analogue thereof can be used in combination with a substance having a c-kit kinase-inhibiting activity to produce an excellent anti-tumor effect.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.